Related Experiment Video
Updated: May 27, 2025
Natural Killer NK and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line
Published on: February 8, 2022
Targeting BCL11B in CAR-engineered lymphoid progenitors drives NK-like cell development with prolonged anti-leukemic
Franziska Baatz1, Arnab Ghosh2, Jessica Herbst1
1Department of Pediatric Hematology, Department of Oncology and Blood Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
Abstract:
Chimeric antigen receptor (CAR)-induced suppression of the transcription factor B cell CLL/lymphoma 11B (BCL11B) propagates CAR-induced killer (CARiK) cell development from lymphoid progenitors. Here, we show that CRISPR-Cas9-mediated Bcl11b knockout in human and murine early lymphoid progenitors distinctively modulates this process either alone or in combination with a CAR. Upon adoptive transfer into hematopoietic stem cell recipients, Bcl11b-edited progenitors mediated innate-like antigen-independent anti-leukemic immune responses. With CAR expression allowing for additional antigen-specific responses, the progeny of double-edited lymphoid progenitors acquired prolonged anti-leukemic activity in vivo. These findings give important insights into how Bcl11b targeting can be used to tailor anti-leukemia functionality of CAR-engineered lymphoid progenitor cells.
Insights
Targeting BCL11B in lymphoid progenitors enhances CAR-engineered cell therapy. Bcl11b knockout promotes antigen-independent anti-leukemic responses, improving CARiK cell efficacy against leukemia.
Area of Science:
- Immunology
- Gene Editing
- Cancer Therapy
Background:
- Chimeric antigen receptor (CAR) therapy shows promise for leukemia treatment.
- CAR-induced suppression of B cell CLL/lymphoma 11B (BCL11B) is crucial for CAR-induced killer (CARiK) cell development.
- BCL11B is a key transcription factor regulating lymphoid cell differentiation.
Purpose of the Study:
- To investigate the role of CRISPR-Cas9-mediated Bcl11b knockout in modulating CARiK cell development and anti-leukemic activity.
- To assess the distinct effects of Bcl11b knockout alone or in combination with CAR expression on lymphoid progenitors.
- To explore the potential of Bcl11b targeting for enhancing CAR-engineered lymphoid progenitor cell therapy.
Main Methods:
- CRISPR-Cas9 gene editing to knockout Bcl11b in human and murine early lymphoid progenitors.
- Generation of CAR-engineered lymphoid progenitor cells.
- Adoptive transfer of edited progenitors into hematopoietic stem cell recipients.
- Evaluation of anti-leukemic immune responses and cell activity in vivo.
Main Results:
- Bcl11b knockout distinctly modulated CARiK cell development in early lymphoid progenitors.
- Bcl11b-edited progenitors demonstrated innate-like, antigen-independent anti-leukemic immune responses post-transfer.
- Lymphoid progenitors with both Bcl11b knockout and CAR expression exhibited prolonged in vivo anti-leukemic activity.
- Combined editing strategy enhanced the overall anti-leukemic functionality.
Conclusions:
- Targeting BCL11B is a viable strategy to enhance the anti-leukemic functionality of CAR-engineered lymphoid progenitor cells.
- Bcl11b knockout can confer antigen-independent anti-leukemic activity, complementing CAR-mediated antigen-specific responses.
- These findings provide a foundation for developing improved CAR-based immunotherapies for leukemia.
Related Concept Videos
01:23Cells of the Adaptive Immune Response
01:24B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...